By Massachusetts Families Organizing for Change (MFOFC)

A Full Life Ahead Series is offered in the Metro Boston Region by Massachusetts Families Organizing for Change in partnership with with Riverside Community Care and Advocates.


A Full Life Ahead: Creating Housing Options 
Thursday, April 13, 2017 6:30 – 8:30 PM
Advocates Main Office, 1881 Worcester Road, Framingham, MA

How can I develop a housing option for my adult child, even if they are not prioritized for residential services? Come learn about governmental funding streams, how they can be combined, and how to supplement them with your own resources. The importance of building your child’s skills will also be discussed.

>> Register

From LPB, “A great day today at the MA State House advocating for people with Down syndrome. Of importance to us – Bill S2157/H4040 to ensure continuation and increased funding for Inclusive Concurrent Enrollment initiative so students with IDD can continue to have inclusive higher education opportunities at MA colleges and universities.”

For more coverage on the MDSC’s Annual Advocacy Day, visit

From LPB, “Lovely to watch this young lady with Down syndrome with the Zumba moves! Won’t you love to try Yulissa Arescurenaga’s class?”

By Tiare Dunlap |

When Yulissa Arescurenaga took her first Zumba class in 2008, she dreamed of one day making it her life’s work by becoming a certified instructor. The only problem was that there were no other instructors out there like Arescurenaga, who has Down syndrome.

From LBP, “The Jerome Lejeune Foundation has been developing therapeutic treatments related to the overexpression of the gene Dryk1A (implicated for causing intellectual disability) for those living with Down syndrome. Clinical trials of interest to us include the use of EGCG, a natural substance found in green tea, as an inhibitor of Dryk1A. They have just announced a new partnership with Manros Therapeutics to develop a new drug from a molecule described in scientific literature as the most powerful inhibitor of Dryk1A.” 

By mbradford |

The Jerome Lejeune Foundation has been intensely involved in supporting the development of therapeutic treatments related to the overexpression of the gene Dryk1A for those living with Down syndrome.